Cheung KS, Chan EW, Wong AYS, et al. - By performing this retrospective cohort analysis, researchers determined statin effect on gastric cancer (GC) development in H. pylori (HP)-eradicated individuals, given that people may still develop GC even following HP eradication. They used a territory-wide electronic healthcare database to recognize all adults who were prescribed clarithromycin-based triple therapy between 2003 and 2012. Cases with GC diagnosed within the first year following index date, prior GC or gastrectomy, and HP treatment failure, were excluded. Participants were observed over a median duration of 7.6 years, during which, the development of GC was reported in 169 (0.27%) of 63,605 patients at an incidence rate of 3.5 per 10,000 person-years. Findings revealed that among HP-eradicated patients, statins associated a lower GC risk in a duration- and dose-response manner.